You are here

  • Home
  • Archive
  • Volume 31, Issue 10
  • Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial

Article metrics

Article menu
Download PDFPDF
Original research
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial

 

Online download statistics by month:

Online download statistics by month: August 2021 to April 2024

AbstractFullPdf
Aug 2021171715
Sep 2021785748
Oct 202118273326
Nov 2021173109
Dec 202112254
Jan 2022131117
Feb 20221291517
Mar 202212576
Apr 2022100115
May 202220131
Jun 202223095
Jul 20229433
Aug 202213922
Sep 202210411
Oct 202210111
Nov 20227131
Dec 20225751
Jan 20239822
Feb 202315145
Mar 20237900
Apr 20233120
May 20235321
Jun 20234621
Jul 20235300
Aug 20236052
Sep 20234210
Oct 20238642
Nov 202311522
Dec 20237953
Jan 20245230
Feb 20248011
Mar 20248751
Apr 20245321
Total4864233173